Previous Close | 47.42 |
Open | 47.28 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 47.16 - 47.47 |
52 Week Range | 33.21 - 53.94 |
Volume | |
Avg. Volume | 351 |
Market Cap | 6.561B |
Beta (5Y Monthly) | 0.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.